The VOYAGER PAD trial was the largest evidence base of patients with revascularised symptomatic PAD, which demonstrated that the combination of twice-daily rivaroxaban and once-daily aspirin was safe and more effective than aspirin alone for reducing future thrombotic and ischaemic events [2]. In the current subgroup analysis of VOYAGER PAD, presented by Prof. William Hiatt (University of Colorado, USA), investigators aimed to evaluate whether efficacy and safety of rivaroxaban were consistent regardless of background clopidogrel use.
The rationale for this particular subgroup analysis was that the dual-antiplatelet therapy (DAPT) in PAD patients who have just undergone endovascular lower-extremity revascularisation usually consists of aspirin and clopidogrel, although this choice is not based on any Class I evidence and instead is "an extrapolation from the coronary artery literature, where it does have some benefit, particularly after percutaneous coronary intervention,” Prof. Hiatt explained.
Here, half of the 6,564 randomised patients enrolled in VOYAGER PAD also received clopidogrel at the time of their lower extremity revascularisation procedure, which was at the discretion of their treating physician and was allowed for up to 6 months. Patients receiving clopidogrel were more likely to undergo endovascular procedures (90.7%) than undergo surgery (9.3%), consistent with the common use of clopidogrel in endovascular procedures.
Results of this pre-specified subgroup analysis demonstrated that the benefit of rivaroxaban + aspirin versus aspirin alone in patients with symptomatic PAD undergoing revascularisation is consistent, regardless of background clopidogrel. The primary efficacy endpoint had a hazard ratio ~0.85 with rivaroxaban, regardless of clopidogrel with number needed to treat <50 with or without clopidogrel. The safety of rivaroxaban + aspirin versus aspirin alone was also consistent regardless of background clopidogrel overall. The principal safety outcome of Thrombolysis in Myocardial Infarction (TIMI) major bleeding had a hazard ratio of ~1.3 to 1.5 regardless of clopidogrel, with number needed to harm >90 with or without clopidogrel.
In an exploratory analysis of early bleeding, exposure to clopidogrel was associated with higher rates of bleeding while used, particularly with longer durations (e.g. >30 days). Prof. Hiatt concluded: "In the absence of clear benefit, clopidogrel exposure along with aspirin and rivaroxaban should be minimised or avoided to reduce this risk." It should be noted that VOYAGER PAD was not designed to assess whether clopidogrel provides any benefit in this setting, a question that remains unanswered.
- Hiatt WR, et al. Abstract 406-13. ACC/WCC 28-30 March 2020.
- Bonaca MP, et al. N Engl J Med. 2020. DOI:10.1056/NEJMoa2000052.
Posted on
Previous Article
« TAILOR-PCI misses endpoint but still provides valuable insights Next Article
Rivaroxaban and aspirin effective and safe for PAD patients »
« TAILOR-PCI misses endpoint but still provides valuable insights Next Article
Rivaroxaban and aspirin effective and safe for PAD patients »
Table of Contents: ACC/WCC 2020
Featured articles
Heart Failure and Cardiomyopathies
Mavacamten shows promising results in non-obstructive hypertrophic cardiomyopathy
Vericiguat shows beneficial effects in a very high-risk HF population
No role for sodium nitrite in out-of-hospital cardiac arrest
Vascular Medicine and Thromboembolism
Rivaroxaban and aspirin effective and safe for PAD patients
TAILOR-PCI misses endpoint but still provides valuable insights
Edoxaban: alternative to warfarin after surgical aortic or mitral valve procedures?
Bleeding reduction post-TAVI with OAC alone vs OAC + clopidogrel
Apixaban offers new perspective for cancer patients in need of anticoagulation
Rivaroxaban superior to enoxaparin in preventing VTE in non-major orthopaedic surgery
Interventional Cardiology
TAVR safe and effective in low-risk bicuspid aortic stenosis patients
TAVR model reveals differences in hospital outcomes
2-year results show non-significant outcomes TAVR vs surgery in severe aortic stenosis
Renal denervation better than sham for blood pressure
Infusion of ethanol in the vein of Marshall for persistent AF
Atrial Fibrillation/Acute Coronary Syndrome
Fewer adverse events with ticagrelor monotherapy after 3 months DAPT
TWILIGHT sub-study: same outcomes for diabetes patients
TWILIGHT sub-study: complex PCI patients
LAAO Watchman registry data positive
Apixaban in AF patients with recent ACS/PCI: Drop aspirin after 30 days
Genetics and Prevention
Homozygous FH responds to alirocumab
Evinacumab significantly reduces LDL-C in homozygous FH patients
Higher serum levels of eicosapentaenoic acid correlate with reduced CV events
Quit smoking: vaping + counselling helps
Related Articles
September 8, 2020
Infusion of ethanol in the vein of Marshall for persistent AF
September 8, 2020
TAVR safe and effective in low-risk bicuspid aortic stenosis patients
September 8, 2020
TWILIGHT sub-study: complex PCI patients
© 2024 Medicom Medical Publishers. All rights reserved. Terms and Conditions | Privacy Policy
HEAD OFFICE
Laarderhoogtweg 25
1101 EB Amsterdam
The Netherlands
T: +31 85 4012 560
E: publishers@medicom-publishers.com